

1st EFSPI Workshop on Regulatory Statistics

September 12-13, 2016 Basel (CH)

Our first Statistical Workshop will be dedicated to opportunities and challenges of statistical topics between regulators, academics and industry with dedicated time for interaction and discussion.

The Scientific Committee consists of: Norbert Benda, Egbert Biesheuvel, Hans Ulrich Burger, Tim Friede, Christoph Gerlinger, Armin Koch, David Wright and Emmanuel Zuber

Outline of the Agenda

Monday Sept 12

13:30 Welcome

13:40 Session 1: Estimands, upcoming guidelines

Speakers: *Thomas Permutt (FDA), Norbert Benda (BfArM)/Frank Pétavy (EMA), Mouna Akacha (Novartis)*

15:10 Coffee break

15:40 Session 2: Implications of Estimands Selection on Labeling

Speakers: *Ann-Kristin Leuchs (BfArM), Kaspar Rufibach/Hans Ulrich Burger (Roche), Chrissie Fletcher (Amgen), Christoph Gerlinger/Michael Kunz (Bayer)*

Panel Discussion

17:30 Reception

Tuesday Sept 13

8:30 Session 3: Extrapolation (e.g. from adults to children)

Speakers: *Jacob Brogren (MPA), Kristin Weber/Armin Koch (MH Hannover), Thomas Dumortier/Steffen Ballerstedt (Novartis)*

10:00 Coffee break

10:30 Session 4: Benefit Risk assessments

Speakers: *David Wright (MHRA), George Quartey (Roche), Alexander Schacht (Lilly)*

12:00 Lunch break

13:00 Session 5: Statistics in Quality and Quality Attributes

Speakers: *Jens Lamerz (Roche), Bruno Boulanger (Arlenda), Thomas Lang (AGES)*

14:30 Coffee break

15:00 Session 6: Contributed short topics – discussions

chairs: *Armin Koch (MH Hannover) and Hans Ulrich Burger (Roche)*

16:30 Closure of the meeting



Venue

Biozentrum
University of Basel
Klingelbergstrasse 50/70
CH – 4056 Basel
Switzerland

Registration Costs

Fee includes lunch & refreshments

Early bird before or on 1st of August

Industry	€250
Academic	€175

After 1st of August

Industry	€300
Academic	€225

TO REGISTER PLEASE GO TO:

www.efspi.org

Or contact:

EFSPI Secretariat
Tel: +44 (0)1625 664549
efspi@kingstonsmith.co.uk

For information regarding the scientific content, contact one of the members of the Scientific Committee

Proposals for short topics for Session 6, please contact either Armin Koch (koch.armin@mh-hannover.de) or Hans Ulrich Burger (hans_ulrich.burger@roche.com) by August 15

1st EFSPi Workshop on Regulatory Statistics Agenda

<u>Monday September 12</u>									
13:30-13:40	Welcome								
13:40-15:10	Session 1: Estimands: Upcoming guidelines Chair: David Wright, Tim Friede								
	<table style="width: 100%; border: none;"> <tr> <td style="width: 60%;"><i>The Per Protocol principle</i></td> <td>Thomas Permutt (FDA)</td> </tr> <tr> <td><i>Estimands in drug approval: the way forward</i></td> <td>Norbert Benda, (BfArM) Frank Pétavy (EMA)</td> </tr> <tr> <td><i>Estimands: are we estimating what we intend to estimate?</i></td> <td>Mouna Akacha (Novartis)</td> </tr> </table>	<i>The Per Protocol principle</i>	Thomas Permutt (FDA)	<i>Estimands in drug approval: the way forward</i>	Norbert Benda, (BfArM) Frank Pétavy (EMA)	<i>Estimands: are we estimating what we intend to estimate?</i>	Mouna Akacha (Novartis)		
<i>The Per Protocol principle</i>	Thomas Permutt (FDA)								
<i>Estimands in drug approval: the way forward</i>	Norbert Benda, (BfArM) Frank Pétavy (EMA)								
<i>Estimands: are we estimating what we intend to estimate?</i>	Mouna Akacha (Novartis)								
15:10-15:40	Coffee break								
15:40-17:10	Session 2: Implications of Estimands Selection on Labelling Chair: Norbert Benda, Egbert Biesheuvel								
	<table style="width: 100%; border: none;"> <tr> <td style="width: 60%;"><i>Regulatory considerations on estimands in specific indications</i></td> <td>Ann-Kristin Leuchs (BfArM)</td> </tr> <tr> <td><i>Estimands for time-to-event endpoints in oncology and beyond</i></td> <td>Kaspar Rufibach and Hans Ulrich Burger (Roche)</td> </tr> <tr> <td><i>Incorporating estimands in the clinical trial protocol</i></td> <td>Chrissie Fletcher (Amgen)</td> </tr> <tr> <td><i>Defining estimands in a pain study – (short case study)</i></td> <td>Christoph Gerlinger and Michael Kunz (Bayer)</td> </tr> </table>	<i>Regulatory considerations on estimands in specific indications</i>	Ann-Kristin Leuchs (BfArM)	<i>Estimands for time-to-event endpoints in oncology and beyond</i>	Kaspar Rufibach and Hans Ulrich Burger (Roche)	<i>Incorporating estimands in the clinical trial protocol</i>	Chrissie Fletcher (Amgen)	<i>Defining estimands in a pain study – (short case study)</i>	Christoph Gerlinger and Michael Kunz (Bayer)
<i>Regulatory considerations on estimands in specific indications</i>	Ann-Kristin Leuchs (BfArM)								
<i>Estimands for time-to-event endpoints in oncology and beyond</i>	Kaspar Rufibach and Hans Ulrich Burger (Roche)								
<i>Incorporating estimands in the clinical trial protocol</i>	Chrissie Fletcher (Amgen)								
<i>Defining estimands in a pain study – (short case study)</i>	Christoph Gerlinger and Michael Kunz (Bayer)								
	Panel discussion								
17:10	Closure of first day								
17:30-19:00	Reception								



<u>Tuesday September 13</u>	
8:30-10:00	Session 3: Extrapolation (e.g. from adults to children) Chair: Tim Friede and Christoph Gerlinger
	<i>Confirmation of extrapolation based on PK/PD data and modelling</i> Jacob Brogren (MPA) <i>On the road to clinical extrapolation</i> Kristina Weber and Armin Koch (MH Hannover) <i>Supporting a paediatric investigation plan in liver transplantation – a pharmacometric approach</i> Thomas Dumortier and Steffen Ballerstedt (Novartis)
10:00-10:30	Coffee break
10:30-12:00	Session 4: Benefit Risk assessments Chair: Thomas Lang (to be confirmed) and Emmanuel Zuber
	<i>Practical Benefit Risk assessment</i> David Wright (MHRA) <i>What's going on in benefit-risk and what is our role as a statistician?</i> Alexander Schacht (Lilly) <i>Benefit-Risk assessment via case studies: key considerations and lessons learned</i> George Quartey (Roche) Panel Discussion
12:00-13:00	Lunch break
13:00-14:30	Session 5: Statistics in quality and quality attributes Chair: Norbert Benda and Hans Ulrich Burger
	<i>The role of statistics in ensuring Quality in pharmaceutical manufacturing</i> Jens Lamerz (Roche) <i>Assessment of analytical biosimilarity: the objective, the challenges and the opportunities</i> Bruno Boulanger (Arlenda) <i>To be confirmed</i> Thomas Lang (AGES)
14:30-15:00	Coffee break
15:00-16:30	Session 6: Contributed short topic – discussions Chair: Armin Koch and Hans Ulrich Burger
	<i>Up to 6 topics from practice will briefly be presented (5 min) followed by a 10-15 min discussion of the panel and with audience</i> <i>Panel members: Norbert Benda, David Wright, Tim Friede, Armin Koch</i> Proposals of topics can be addressed until August 15 to either Armin Koch (koch.armin@mh-hannover.de) or Hans Ulrich Burger (hans_ulrich.burger@roche.com)
16:30-16:35	Closure of the meeting